Experimental HBV Drugs
Immune-Based Therapy GS-9620 Shows Promise for Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 12 April 2011 03:38
- Written by Liz Highleyman
Gilead's GS-9620, an experimental TLR7 agonist, stimulated interferon production and activated B-cells and T-cells in laboratory and human studies, and was active against hepatitis B and a related virus in monkeys and woodchucks, researchers reported at EASL 2011.
Safety Review Clears Continuation of Hepislav Hepatitis B Vaccine
- Details
- Category: Experimental HBV Drugs
- Published on Friday, 04 June 2010 12:49
- Written by Dynavax
Dynavax Technologies announced this week that a Data Safety Monitoring Board has reviewed interim data from more than 2000 participants in 2 Phase 3 studies of the company's investigational hepatitis B vaccine, Hepislav, and determined that the trial may go forward without modification.
Investigational 2-Dose Dynavax Heplisav Hepatitis B Vaccine May Work Better than Standard 3-Dose Energix-B Vaccine
- Details
- Category: Experimental HBV Drugs
- Published on Tuesday, 12 May 2009 13:47
- Written by HIVandHepatitis.com
An investigational hepatitis B virus (HBV) vaccine may offer the same degree of protection with 2 doses as the standard Engerix-B vaccine does with 3 doses, according to a study presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen.
EASL 2010: Tenofovir/emtricitabine (Truvada) Prevents Hepatitis B Recurrence after Liver Transplantation in Patients with Mild Kidney Impairment
- Details
- Category: HBV Treatment
- Published on Tuesday, 20 April 2010 13:55
- Written by Liz Highleyman
Combination therapy using tenofovir (Viread) plus emtricitabine (Emtriva) -- the 2 drugs in the Truvada coformulation -- either with or without injected hepatitis B virus (HBV) antibodies, was well tolerated and prevented HBV recurrence in chronic hepatitis B patients with mild-to-moderate kidney (renal) impairment who underwent liver transplantation, according to a study presented last week at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) in Vienna.
Addition of Emtricitabine (Emtriva) Does Not Improve Response to Tenofovir (Viread) for Chronic Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 05 May 2009 13:47
- Written by Liz Highleyman
As described in a poster presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen, T. Berg and an international team of colleagues conducted Study 106, comparing the efficacy of tenofovir/emtricitabine combination therapy versus tenofovir alone for the treatment of chronic hepatitis B.